Tablet

Dapagliflozin 10mg

Dapagliflozin Propanediol

Broad-spectrum SGLT-2 inhibitor with triple regulatory approvals for type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease — the widest indication set in its class. DAPA-HF and DAPA-CKD trials demonstrated transformational reductions in CKD progression and HF hospitalization independent of diabetes status.

Strengths

5mg / 10mg

Packing

10 tablets/strip

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request Quotation WhatsApp

Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition

Dapagliflozin Propanediol Monohydrate equivalent to Dapagliflozin 5mg / 10mg

Dosage Form

Tablet

Available Strengths

5mg / 10mg

Packing

10 tablets/strip

Route of Administration

Oral, with or without food

Dosage

10mg once daily; 5mg in patients with volume depletion or eGFR 25-45 for diabetes indication; 10mg for HF and CKD

Indications

Type 2 diabetes, heart failure with reduced ejection fraction (with or without diabetes), chronic kidney disease (to reduce eGFR decline)

Country of Origin

India (WHO-GMP Certified)

Storage

Store at 25°C

Shelf Life

36 months

Side Effects

Genital mycotic infections, UTI, polyuria, volume depletion, DKA (rare), Fournier's gangrene (rare)

Precautions

Not for type 1 diabetes (except specific indication); monitor renal function; withhold before major surgery; DKA risk; avoid if eGFR <25 for diabetes indication; genital hygiene counseling

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Tablet

Glimepiride 2mg

Glimepiride

Third-generation sulfonylurea that stimulates pancreatic beta-cell insulin secretion via selective SUR1 receptor binding, offering a lower hypoglycemia risk compared to earlier sulfonylureas due to glucose-dependent activity. The most cost-effective oral antidiabetic agent in its class and a cornerstone of type 2 diabetes management in emerging markets.

1mg / 2mg / 3mg / 4mg

Tablet

Sitagliptin 100mg

Sitagliptin Phosphate

First-in-class DPP-4 inhibitor that amplifies incretin-mediated glucose-dependent insulin secretion while suppressing glucagon, offering glycemic control without weight gain or intrinsic hypoglycemia risk. Once-daily dosing, renal dose adjustment flexibility, and a decade-long cardiovascular safety record make it a globally preferred add-on antidiabetic.

25mg / 50mg / 100mg

Tablet

Vildagliptin 50mg

Vildagliptin

Selective DPP-4 inhibitor with potent enzyme inhibition that improves glycemic control through enhanced incretin-mediated insulin secretion and suppressed post-meal glucagon release. Widely prescribed as a fixed-dose combination with metformin (Galvusmet) offering convenient dual-mechanism therapy without weight gain.

50mg

Need bulk pricing for Dapagliflozin 10mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote